EUVIMEDEUVIMED entdecken
Crossref

Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma

Hui Yu iD, Jin Chai iD, Jiaowu Cao, Dingyao Hu iD, Zhao Jin iD, Yanxiang Li, Jie Lv, Jie Chen iD, Yue Wang iD, Wenhui Zhang, Jun Zhu iD, Yuqin Song iD

Hematological Oncology · 2026

DOI: 10.1002/hon.70266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Hui Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Inst…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Agammaglobulinaemia Tyrosine Kinase, CD4-Positive T-Lymphocytes, Lymphoma, B-Cell. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Xisike Clinical Oncology Research Foundation, Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B‐cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively evaluated associations between peripheral immune profiles and outcomes in 40 patients treated with CD20 × CD3 BsAbs and explored BTK inhibitor–associated immune changes using a paired BTK inhibitor cohort, functional assays, mouse models, and single‐cell RNA sequencing. Higher baseline CD4 + T‐cell counts correlated with superior response rates and prolonged progression‐free survival, whereas CD8 + counts showed no association. Elevated CD4 + T‐cell levels were linked to increased activation of effector CD8 + CD28 + T cells and greater induction of IL‐2 and IFN‐γ following treatment. Across paired clinical samples and experimental models, BTK inhibition was associated with CD4 + T‐cell expansion and enhanced T/NK‐cell proliferative and cytotoxic signatures. In an exploratory real‐world observation, three patients received BTK inhibition before glofitamab; all achieved complete responses, with two remaining in remission at data cutoff and one relapsing after 8.4 months. These findings identify peripheral CD4 + T‐cell reserve as a potential biomarker associated with BsAb outcomes and provide a rationale for further investigation of BTK inhibitor–mediated immune modulation in BsAb treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAgammaglobulinaemia Tyrosine KinaseCD4-Positive T-LymphocytesLymphoma, B-CellAntigens, CD20CD3 ComplexProtein Kinase InhibitorsHumansAnimalsFemaleMaleBiomarkers, TumorMiceRetrospective StudiesMiddle AgedAged

Stichwörter der Autor:innen

BTK inhibitorB‐cell lymphomaCD4+ T cellbiomarkerbispecific antibody (BsAb)immune modulation

Substanzen

Antibodies, BispecificAgammaglobulinaemia Tyrosine KinaseBTK protein, humanAntigens, CD20CD3 ComplexBiomarkers, TumorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Health Care, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • King's College, London, UK.

ORCID-Profile: Hui Yu, Jin Chai, Dingyao Hu, Zhao Jin, Jie Chen, Yue Wang, Jun Zhu, Yuqin Song

Förderung

  • National Natural Science Foundation of China
  • Beijing Xisike Clinical Oncology Research Foundation
  • Science Foundation of Peking University Cancer Hospital

Zitieren

APA

Yu, H., Chai, J., Cao, J., Hu, D., Jin, Z., Li, Y., Lv, J., Chen, J., Wang, Y., Zhang, W., Zhu, J., & Song, Y. (2026). Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70266

Vancouver

Yu H, Chai J, Cao J, Hu D, Jin Z, Li Y, et al. Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma. Hematological Oncology. 2026. doi:10.1002/hon.70266

BibTeX
@article{Yu2026,
  author = {Yu, Hui and Chai, Jin and Cao, Jiaowu and Hu, Dingyao and Jin, Zhao and Li, Yanxiang and Lv, Jie and Chen, Jie and Wang, Yue and Zhang, Wenhui and Zhu, Jun and Song, Yuqin},
  title = {Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70266}
}
Kostenlos starten →